This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Clinical trial NCT03449381 · COMPLETED
Trial details
- NCT number
- NCT03449381
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-20
- Primary completion
- 2025-11-13
- Enrollment
- 266
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.